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EphA3 as a target for antibody immunotherapy in acute
lymphoblastic leukemia
S Charmsaz1,2,3, F Al-Ejeh4, TM Yeadon1, KJ Miller1, FM Smith1, BW Stringer1, AS Moore5, F-T Lee6, LT Cooper1, C Stylianou1,
GT Yarranton7, J Woronicz7, AM Scott6, M Lackmann8 and AW Boyd1,2
The human EphA3 gene was discovered in a pre-B acute lymphoblastic leukemia (pre-B-ALL) using the EphA3-speciﬁc monoclonal
antibody (mAb), IIIA4, which binds and activates both human and mouse EphA3. We use two models of human pre-B-ALL to
examine EphA3 function, demonstrating effects on pre-B-cell receptor signaling. In therapeutic targeting studies, we demonstrated
antitumor effects of the IIIA4 mAb in EphA3-expressing leukemic xenografts and no antitumor effect in the xenografts with no
EphA3 expression providing evidence that EphA3 is a functional therapeutic target in pre-B-ALL. Here we show that the therapeutic
effect of the anti-EphA3 antibody was greatly enhanced by adding an α-particle-emitting 213Bismuth payload.
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INTRODUCTION
Eph receptors, the largest family of receptor tyrosine kinases,
interact with ephrin ligands to regulate cell growth, positioning
and migration.1,2 Eph and ephrin genes are highly expressed in
various embryonic tissues.3–5 High expression of Eph genes were
also observed in many cancers including leukemias, where both
tumor-promoting and -inhibitory effects have been described.2,6
EphA3 was identiﬁed in murine embryos and in human
pre-B-ALL.7,8 EphA3 expression is very low in adult tissues but
high expression is described in cancers, including leukemia,
sarcoma, melanoma and glioblastoma.2,9 Expression was detected
in stromal cells of the tumor microenvironment in several
solid tumors.10 EphA3 copy number variation was observed in
leukemias and EphA3 was identiﬁed as a cooperative response
gene responsible for leukemia stem cell maintenance.11,12
The EphA3-speciﬁc monoclonal antibody (mAb), IIIA4, binds
and activates human and mouse EphA3,13 inducing internalization
of receptor-antibody complexes.9 In glioblastoma cells, EphA3
knockdown reduced tumorigenicity in mice and treatment with
radiolabeled IIIA4 antibody induced tumor regression of glioblas-
toma xenografts.14 In some tumors, IIIA4 antibody targeting of
EphA3-positive stromal cells led to inhibition of tumor growth by
disruption of architecture and function of vascular elements.10
These studies established EphA3 as a therapy target and KaloBios
Pharmaceuticals Inc. (Brisbane, CA, USA) developed a Humaneered
derivative of the original IIIA4 anti-EphA3 mAb (KB004) for which
clinical trial is underway in hematological malignancies.
In this study, we show that IIIA4 antibody treatment of EphA3-
positive human pre-B-ALL xenografts results in a direct anti-
leukemic effect and an antibody-mediated effect on tumor cell
spread to distant sites. We show that this effect is directed
speciﬁcally at leukemic cells, and that payload delivery by IIIA4 is
highly effective for antileukemia therapy.
MATERIALS AND METHODS
Cell culture and patient samples
The LK63 cell line was generated in our laboratory,15 and other cell lines were
obtained from the American Type Culture Collection (ATCC, Manassas, VA,
USA). Cells were maintained in RPMI1640 supplemented with 10% fetal-
calf-serum. LK63/A3KD (LK63 EphA3-knockdown) cells were derived as
previously described.14 Reh/EphA3 (Reh EphA3-expressing) cells generated
by infecting Reh cells with EphA3-encoding lentiviral particles (GeneCopoeia,
Rockville, MD, USA; Supplementary Figure 1). Transfected cell lines (Reh/
luciferase, LK63/luciferase, Reh/EphA3, LK63/A3KD) were maintained in
RPMI1640 supplemented with 10% fetal-calf-serum with 0.5 μg/ml puromycin.
Patient samples were obtained from Queensland Children’s Tumor Bank
in accordance with Human Ethics Committee-approved procedures for
consent and sample collection.
Antibodies and Eph fusion proteins, ﬂow cytometry and western
blotting
In-house IgG1 mAbs and IIIA4 anti-EphA3 antibody were used. Mouse anti-
human immunoglobulin M (IgM) antibody δADA4-4 was obtained from the
ATCC. EphrinA5-Fc was used for activating EphA3. Alexa Fluor 488 goat
anti-human IgG (A-11013; Life Technologies, Carlsbad, CA, USA) used as a
secondary antibody.
Anti-human CD45-PE/Cy7 (304016; BioLegend, San Diego, CA, USA), anti-
mouse CD45-APC (103112; Biolegend) and SYTOX-Blue (Life Technologies)
viable cell markers were used to enumerate hematopoietic cells. Flow
cytometric analysis was performed on a BD LSRFortessa (BD Biosciences,
San Jose, CA, USA).
Antibodies used for western blot were as follows: EphA3 in-house
antibody, FYN (4023S; Cell Signaling Technology, Inc., Danvers, MA, USA),
p-FYN (SAB4301504; Sigma, St Louis, MO, USA) SRC (2108; Cell Signaling
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Technology, Inc.,), p-SRC (2101 Tyr416; Cell Signaling Technology, Inc.,) and
β-actin (Sigma).
Amnis ImageStream
ImageStream was used for imaging ﬂow cytometry (Amnis Corporation,
Seattle, WA, USA).16 Cells were incubated with IIIA4 mAb or ephrinA5-FC
preclustered with anti-human IgG and analyzed at time 0 and 20 min after
incubation at 37 °C. Cell surface was stained with PKH26 (PKH26GL; Sigma).
Cells were acquired on ImageStream using INSPIRE software and data were
analyzed using IDEA software (Amnis Corporation). Internalization score is
deﬁned as the ratio of the intracellular signal intensity (intracellular mask)
to the total cell intensity. Negative scores indicate predominant membrane
expression and positive score indicates internalization. Colocalization is
calculated as the correlation between the bright spots on or inside of
the cells.
Gene expression microarrays and analysis
Reverse transcriptase-PCR performed as described previously14 and
primers are listed in Supplementary Table 3.
Microarray gene expression proﬁling performed with a minimum of two
experimental replicates by the Australian Genome Research Facility (AGRF,
Melbourne, Victoria, Australia) using HumanHT-12 array chips (Illumina, San
Diego, CA, USA). Data were analyzed using BRB-ArrayTools17 (V.4.5; Biometric
Research Branch, Bethesda, MD, USA) as described.18 Additional details
are provided in Supplementary Methods and summarized in Supplementary
Tables 1 and 2 and Supplementary Figure 2. Ingenuity Pathway Analysis was
described previously.18
Leukemic xenograft model
Mice were kept at QIMR-Berghofer Medical Research Institute (Brisbane,
QLD, Australia) pathogen-free facility according to QIMR-Berghofer Medical
Research Institute protocols. Xenografts established by tail vein injection of
5 × 106 LK63, Reh, LK63/A3KD and Reh/EphA3 cells into 6–8-week-old
NOD/SCID mice. Xenografts were randomized to treatment groups (43/
per group) and received intraperitoneal injection of anti-EphA3 mAb
(100 μg), control IgG antibody or vehicle (phosphate-buffered saline (PBS)),
from day one and then every second day until the mice were euthanized
due to disease progression. Mice were monitored for weight loss (scores
0–2), body posture (scores 0–2), activity level (scores 0–2) and grooming
(scores 0–2). Mice were euthanized once the total score was 46.
213Bi-IIIA4 study
Bismuth-213 (213Bi) was used to radiolabel cIIIA4 and isotype control
antibodies as described previously.19 To assess biodistribution of radio-
conjugates, mice were treated with 213Bi-cIIIA4 or 213Bi-isotype control at
6.0 μCi/28 μg in 0.1 ml saline 14 days post LK63 injection. Mice were
euthanized at various time points and tissues were harvested for weighing
and radioactive measurement in a dual gamma scintillation counter (Cobra
II Auto Gamma, Packard Instruments, CT, USA).
The efﬁcacy of 213Bi-cIIIA4 α-emitter radioimmunotherapy was assessed in
leukemic xenografts generated with intravenous injection of 13×106 LK63
cells using two treatment regimens. In the ﬁrst study, xenografts were injected
with antibody intravenously at day 6 and in the second study xenografts
received doses of treatment at days 2, 3, 5 and 6 after LK63 injection. In both
studies, treatment groups comprised individual 213Bi-cIIIA4 doses of 12.5 μCi
(115 μg protein) or 25 μCi (180 μg protein) or 213Bi-isotype control 12.5 μCi
(75 μg protein) or 25 μCi (150 μg protein), delivered in 0.1–0.3 ml saline.
Statistics
Statistical analyses were performed using the GraphPad Prism Version 6.01
software (GraphPad Prism, San Diego, CA, USA). Data are shown as mean±
s.e.m./s.d. of at least three replicates, unless stated otherwise. Signiﬁcance was
determined using an unpaired t-test or one-way analysis of variance with a
minimal level of signiﬁcance of Po0.05. Survival of the control and the
Figure 1. Eph expression in leukemic cell lines. (a) Expression of EphA1, EphA2, EphA3 and EphA4 mRNA per 1000 β-actin using RT-PCR.
(b) Flow cytometric expression analysis of EphA3 in leukemic cells. (c) Flow cytometric expression analysis of EphA3 using IIIA4 antibody in
patient samples (n= 30). (d) Representative overlay of ﬂow cytometric analysis of EphA3 on patient samples.
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treatment groups was compared using Kaplan–Meier analysis and statistical
differences analyzed using the log-rank test.
RESULTS
Expression of Eph receptors in leukemic cells
EphA expression in leukemia was assessed in a panel of leukemic
cell lines and 30 clinical samples. Expression analysis in leukemic
cells showed EphA3 as one of the highly expressed EphA
transcripts (Figure 1a). Flow cytometric analysis showed high
expression of EphA3 protein in LK63 and Jurkat, moderate expres-
sion in Molt-4 and no expression in Reh cells20–23 (Figure 1b).
Expression of EphA3 was then assessed in 30 acute leukemias with
different karyotypes (t(1;19)E2A-PBX, t(12;21)ETV6-RUNX1, hyper-
diploid450 chromosomes, trisomy 4/10, MLL-rearranged, BCR-
ABL1 and normal karyotype). Although none of the samples with
MLL rearrangement and BCR-ABL1 showed EphA3 expression,
modest and high expression of EphA3 was detected in one-third
(10/30) of cases. EphA3 was most frequently expressed in pre-B-
ALL with t(1;19)E2A-PBX karyotype (4/8) with two of the samples
having expression levels similar to the t(1;19) bearing LK63 cell
line (Figures 1c and d).15
Characterization of LK63 and Reh xenografts
Xenograft models included EphA3-positive (LK63), LK63/A3KD,
EphA3-negative (Reh) and Reh EphA3-expressing (Reh/A3) cells. In
Figure 2. Leukemia progression in xenograft models. (a) Flow cytometry gating strategy: hCD45 and mCD45. (b) Leukemia progression in
blood, spleen and bone marrow of LK63 xenograft (n= 3). (c) Spleen weight of LK63 xenograft (n= 3 per time-point) compared with normal
mouse (n= 1 per time-point). (d) Histology of normal spleen. (e) Histology of spleen from LK63 xenograft. (f) Reduced spleen size in LK63/
A3KD compared with LK63 xenografts (Po0.0001; n= 4 LK63, n= 5 LK63/A3KD). (g) Signiﬁcant reduction in the spleen and bone marrow
engraftment of LK63/A3KD xenograft compared with LK63 xenograft (P= 0.02) (n= 3 LK63, n= 5 LK63/A3KD). (h) Leukemia progression in
blood, spleen and bone marrow of Reh xenograft. (i) Spleen weight of Reh xenograft (n= 3 per time-point) compared with normal mice (n= 1
per time-point). Data presented as mean percentage± s.e.m. Unpaired t-test performed for statistical analyses.
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the LK63 xenografts, cells grew in the bone marrow before
inﬁltrating into the spleen and peripheral blood (Figure 2b).
Splenic inﬁltration was identiﬁed as discrete foci of proliferating
LK63 cells that became conﬂuent (Figures 2c–e), consistent with
the notion that leukemic cells were seeded into the spleen from
the bone marrow. Engraftment of LK63/A3KD cells was slower
than control LK63 cells, but the most striking difference was their
considerably smaller spleen size (Po0.0001; Figure 2f). There was
also a signiﬁcant reduction in bone marrow engraftment (P= 0.02)
and no differences in spleen engraftment in LK63/A3KD xeno-
grafts compared with control LK63 xenografts (Figure 2g).
Reh engraftment was slower than LK63 xenografts. Cells
preferentially grew in the bone marrow followed by the peripheral
blood, evident once bone marrow engraftment was450%. Unlike
LK63 xenografts, Reh xenografts showed minimal splenic engraft-
ment and no increase in spleen weight (Figures 2h and i).
Gene expression proﬁling of the LK63/A3KD cells compared
with EphA3-high LK63 cells and the EphA3-negative Reh cells to
identify differentially regulated genes (Supplementary Figure 2).
B-cell activation was the biological process shared between these
independent analyses (Supplementary Tables 1 and 2). We
investigated 405 overlapping genes that were affected by EphA3
modulation in these cell lines (Supplementary Tables 1 and 2).
As expected, EphA3 was among the overlapping genes, being
downregulated in LK63/A3KD cells vs LK63 cells but upregulated
in LK63 cells vs Reh cells. Network of interactions from the
405 deregulated genes (234 overexpressed (OE) and 171
underexpressed (UE) genes) was generated from the STRING
database using evidence based on experiments/coexpression
(Figure 3a). Notably, there was less CD79A and CD79B expression
in LK63 compared with LK63/A3KD and Reh cells. As key elements
of the B-cell receptor complex, we asked if increased CD79A
correlated with an increase in BCR expression. We showed that
surface IgM expression was indeed increased in LK63/A3KD
compared with control LK63 cells (Figure 3b). Furthermore, as
apparent from the network (Figure 3a), EphA3 acting on FYN is a
likely mechanism driving gene expression changes in this
network. The effect of EphA3 knockdown and activation on FYN
phosphorylation showed that EphA3 activation in LK63 cells led to
increased FYN phosphorylation. However less phosphorylated FYN
was detected in LK63/A3KD, as expected, and IIIA4 induced less
EphA3 activation and did not induce FYN phosphorylation in
these cells (Supplementary Figure 3 and Figure 3c). FYN total
protein was decreased in LK63/A3KD cells (Figure 3d).
Treatment of xenografted mice with IIIA4 mAb results in
retardation of leukemic growth
The functional effects of EphA3 demonstrated in the LK63 model
prompted us to test whether the IgG1 IIIA4 anti-EphA3 antibody
could elicit a direct antitumor effect. As this isotype does not
mediate effective Fc-mediated immune cell targeting, the variable
region of the original IIIA4 antibody was engineered into both a
murine-IgG2a backbone (IIIA4-IgG2a) and a human-IgG1 back-
bone (cIIIA4). The original IIIA4 antibody had a direct effect on
d
Figure 3. Gene expression proﬁling after EphA3 modulation in LK63 and Reh cells. (a) Analysis of the deregulated genes in LK63 cells after
EphA3 knockdown or in comparison with the EphA3-negative Reh cells, revealed a possibility that EphA3 affects CD79A/B and FYN expression
to mediate the changes of expression of the genes in the network. (b) Flow cytometry of LK63/A3KD cells using IIIA4 and increased expression
of CD79A/B demonstrated by increased IgM expression. (c) Western blots for FYN phosphorylation (Y530). (d) Western blot for total-FYN
protein in LK63 and LK63/A3KD before or after EphA3 activation by ephrinA5-FC. The bands intensity was normalized to the Actin-control and
the fold change compared with LK63 without EphA3 activation was calculated and shown under each lane.
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growth, which minimally increased when the Fc was optimal for
antibody-mediated cell cytotoxicity even in the NOD/SCID mice.
Effective antibody-mediated cell cytotoxicity against LK63 was
demonstrated using human effector cells and defucosylated,
humaneered KB00424 (Supplementary Figure 4) where this
optimized IIIA4 derivative showed signiﬁcant killing of LK63 cells,
whereas the cIIIA4 antibody was less effective.
As defucosylation does not affect murine ADCC, we used cIIIA4
in subsequent experiments. A dose–response experiment in LK63
xenografts demonstrated a maximum therapeutic response at
100 μg per dose (~4 mg/kg) of cIIIA4 (Figure 4a). In subsequent
experiments, 100 μg of cIIIA4 antibody was administered on alter-
nate days starting immediately after xenografting. Neither control
human-IgG1 mAb nor vehicle showed an effect on engraftment
(Figures 4b and c).
As LK63 is positive for CD20, we also analyzed the effect of anti-
CD20 (Mabthera) treatment on LK63 xenografts. The result showed
no signiﬁcant effect on leukemic progression (Supplementary
Figures 4E–G).
Treatment of LK63 xenografts with cIIIA4 signiﬁcantly reduced
spleen engraftment (Po0.0001) as evident by the reduction in
human CD45-positive cells in the spleen and reduced spleen weight
(P=0.0006) compared with controls. Bone marrow engraftment was
also reduced compared with controls (Figures 4d and e). Treatment
of EphA3-negative Reh xenografts with cIIIA4 caused no signiﬁcant
changes in spleen size and spleen and bone marrow engraftment
(Figures 4f and g).
To extend these results, cIIIA4 antibody treatment was also
investigated using LK63/A3KD and Reh/A3 cells. Treatment of
LK63/A3KD xenografts did not affect the spleen and bone marrow
Figure 4. LK63 and Reh xenograft were treated with vehicle or cIIIA4 mAb. (a) Reduced spleen engraftment in LK63 xenograft at 30, 100, 250
and 1000 μg of cIIIA4 compared with vehicle treatment (Po0.0001). No signiﬁcant difference between 100, 250 and 1000 μg cIIIA4 dosing
(n⩾ 4). (b) Percentage of bone marrow engraftment in LK63 xenografts in response to PBS, IgG-control and cIIIA4 at 100 μg (n= 8). (c) Reduced
splenic engraftment in 100 μg cIIIA4-treated LK63 xenografts compared with PBS and IgG-control treatment (Po0.0002, n= 8). (d) Signiﬁcant
reduction in cIIIA4-treated LK63 xenograft spleen weight (P= 0.0006) and engraftment (Po0.0001) compared with PBS. There were no
signiﬁcant reduction in bone marrow engraftment (n= 16 PBS, n= 17 IIIA4, four experiments). (e) Representative Xenogen images of LK63
xenografts day 9, 14, 18 and 22. (f) No differences in spleen weight, spleen and bone marrow engraftments of Reh xenografts treated with
cIIIA4 or PBS (n= 15, three experiments). (g) Representative Xenogen images of Reh xenografts days 14, 18, 25 and 29. Point in graphs (d) and
(e) corresponds to one mouse. Data presented as mean percentage± s.e.m. Unpaired t-tests or one-way analysis of variance (ANOVA)
performed for statistical analyses.
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engraftment compared with controls (Figures 5a and b).
Importantly, unlike Reh xenografts, treatment of Reh/A3 xeno-
grafts with cIIIA4 caused signiﬁcant reduction in bone marrow
(P= 0.0072) and spleen (P= 0.0464) engraftment compared with
controls (Figures 5c and d).
To simulate human leukemia where disease originates in bone
marrow and then spreads to blood and other organs, Reh or LK63
cells were directly injected into the right femoral marrow cavity
(Supplementary Methods). In both cases, leukemic deposits
formed at the injection site followed by inﬁltration in other bones
(left femoral), before spread to other organs. For LK63 cells, similar
to the intravenous xenograft model extensive splenic inﬁltration
was seen. Both models were treated with vehicle or cIIIA4 mAb
and the response to cIIIA4 mimicked the intravenous model
(Supplementary Figure 5).
EphrinA5 and cIIIA4 antibody induced internalization of EphA3
While the direct effect of cIIIA4 treatment in LK63 and Reh/A3
xenografts resulted in signiﬁcant antitumor effect, this translated
into a modest increase in survival. Therefore, to determine
whether an antibody linked with a cytotoxic payload may be
more efﬁcacious, the degree of IIIA4 antibody internalization was
explored.
LK63 and Reh cells were incubated with preclustered huIgG,
IIIA4, preclustered IIIA4 or preclustered ephrinA5-Fc to induce
receptor clustering and activation. As presented in Supplementary
Figure 3, transient receptor phosphorylation was induced by these
stimuli and preclustered antibody also induced phosphorylation of
SRC, a known target of Eph signaling.25 Internalization of IIIA4 and
ephrinA5-FC was analyzed in LK63 cells using AMNIS imaging ﬂow
cytometry at time 0 and 20 min after incubation at 37 °C where an
increased internalization score upon treatment with IIIA4 antibody
or ephrinA5-FC was observed. Internalization induced by ephrinA5
is in accordance with previous data26 (Figure 6).
213Bi-IIIA4 therapy
Having demonstrated IIIA4-induced EphA3 internalization, we
asked if a therapeutic cytotoxic payload could be delivered with
minimal toxicity. 213Bi-cIIIA4 and control 213Bi-labeled antibodies
were prepared at respective speciﬁc activities of 109 and 167 μCi/
mg for in vitro and in vivo characterization.
Biodistribution of 213Bi-radiolabeled cIIIA4 and isotype control
was determined in LK63 xenografts showing that 213Bi-cIIIA4
localized to the areas of leukemia involvement within 15 min of
injection and were maintained over 3 h. Peak uptake of 20.8 ± 3.9
and 20.9 ± 3.8% ID/g was observed after 2 h in the liver and
spleen, respectively. Minimal uptake (0.2–6% ID/g) was observed
in other normal tissues at all time points (Figure 7a). The speciﬁcity
of the 213Bi-cIIIA4 for EphA3-positive leukemia conﬁrmed by low
levels of tissue localization observed with the isotype control
antibody (Figure 7b).
A single dose of 213Bi-cIIIA4 radioimmunotherapy in the LK63
xenografts 6 days after LK63 injection showed no signiﬁcant
differences in the median survival between the treatment groups
(Figure 7c). However, four doses of 213Bi-cIIIA4 induced a highly
signiﬁcant increase in survival. Median survival of the control
group was 21 days, whereas multidose treatment with unlabeled
IIIA4 or 12.5 μCi 213Bi-isotype control caused an increase in median
survival to 24 days. Radioimmunotherapy with 213Bi-cIIIA4
signiﬁcantly increased survival in a dose-dependent manner with
a median survival of 26.5 days at 12.5 μCi and 41.5 days at 25 μCi
multidose treatment. The speciﬁcity of the cIIIA4 radioimmu-
notherapy is indicated by the signiﬁcantly longer survival
compared with the 213Bi-isotype control groups (Figure 7d).
DISCUSSION
Expression of EphA3 in leukemia and the low expression on
normal tissues led us to investigate the potential of EphA3 as a
therapeutic target in ALL.27 We showed that EphA3 was expressed
in ~ 1/3 of ALL cases and appears to be more signiﬁcantly
expressed in some subgroups, particularly cases having the t(1;19)
translocation. Although only four cases with MLL translocations
were tested, taken together with our previous data,28 it seems
unlikely that EphA3 would be expressed in these leukemias as MLL
transcriptionally induces expression of other Eph receptors with
redundant function. Therapy with anti-EphA3 antibody was
investigated using xenografts of the EphA3-positive (LK63, Reh/
A3) and the EphA3-negative/low (Reh, LK63/A3KD) cell lines. In
these models, leukemic cells preferentially grew in the bone
marrow after intravenous xenotransplantation. However, in LK63,
unlike Reh and Reh/A3 xenografts, secondary engraftment in the
spleen preceded signiﬁcant colonization of other organs and
peripheral blood. When EphA3 expression was reduced in LK63/
A3KD, the leukemic process was similar, except that splenic
involvement was less marked. These patterns were conﬁrmed by
implanting cells directly into the bone marrow and showing that
spread and growth in other bone marrow sites preceded systemic
spread.
Microarray analysis of the LK63, LK63/A3KD and Reh cell lines
identiﬁed elements of the B-cell receptor signaling complex (BCR),
CD79A, CD79B and downstream effectors, particularly FYN, as
Figure 5. LK63/A3KD and Reh/A3 xenografts treated with vehicle
or cIIIA4 mAb. (a) No differences in spleen weight of LK63/A3KD
xenografts treated with cIIIA4 or vehicle (b) No differences in spleen
and bone marrow engraftment of LK63/A3KD xenograft treated with
cIIIA4 or PBS (n=13 PBS, n=14 cIIIA4, three experiments). (c) No
differences in spleen weight of Reh/A3 xenograft treated with cIIIA4 or
vehicle (n=9 PBS, n=9 cIIIA4, three experiments). (d) Reh/A3 bone
marrow (P=0.0072) and spleen (P=0.0464) engraftment were
signiﬁcantly reduced in cIIIA4-treated compared with PBS control
(n=14 PBS, n=14 cIIIA4, four experiments). Each point in graphs
(a) and (c) corresponds to one mouse. Data presented as mean
percentage±s.e.m. Unpaired t-test performed for statistical analyses.
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differentially expressed in the presence of EphA3. Notably, IIIA4
antibody treatment resulted in an increase in phosphorylated FYN
in LK63 cells but not in LK63/A3KD cells. However, increased
CD79A levels in LK63/A3KD cells were correlated with increased
surface IgM expression. As in normal pre-B cells, BCR signaling
strength is important for survival of pre-B ALL cells.29,30 In
particular, excessive BCR signaling was shown to lead to cell death
in leukemic cells, suggesting that EphA3 may act by reducing BCR
signaling strength and thus promoting leukemic cell survival.
In LK63 xenografts, administration of either the mouse-IgG1 or
the human-IgG1 cIIIA4 antibody resulted in inhibition of leukemia
marrow inﬁltration, marked delay in tumor spread to spleen and
other organs and increased in the latency of the disease. This is
consistent with a direct effect of the mAb with some augmenta-
tion when Fc-mediated effects were present. In EphA3-negative
Reh xenografts, no therapeutic effect was observed, suggesting
that the effect of cIIIA4 mAb treatment was directed against
leukemic cells expressing EphA3, rather than tumor micro-
environment.10 In keeping with the lack of effect of cIIIA4
treatment on Reh xenografts, cIIIA4 treatment of LK63/A3KD
xenografts showed considerably less effect on disease progres-
sion. However, treating Reh/A3 xenografts with cIIIA4 resulted in a
signiﬁcant reduction in bone marrow and spleen engraftment,
comparable to the effect observed in LK63 xenografts. These
results conﬁrmed that in these leukemic models, in contrast to the
solid tumor models reported by Vail et al.,10 the effect of cIIIA4
Figure 6. Effect of EphA3 activation on signaling and internalization. (a) Representative images of treated cells at 0 and 20 min. (b) Increase in
internalization score upon IIIA4 or ephrinA5-Fc treatment after 20min incubation at 37 °C in LK63 cells. (c) Median internalization score upon
IIIA4 and ephrinA5-Fc treatment at 0 or 20 min after incubation at 37 °C in LK63 cells. (d) Percentage of cells that are internalized or colocalized
at time 0 or 20 min after IIIA4 or ephrinA5-Fc treatment. In each AMNIS experiment, 5000 cells were collected and the experiment was
repeated two times.
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treatment was speciﬁcally directed against the leukemic cells with
no detectable effect on tumor stromal elements.
Despite evidence for both a direct effect of the antibody on the
leukemic cells and some augmentation when effective Fc-
mediated function was present, there was only a limited effect
on overall survival. The report of the ﬁrst human trial of the ADCC-
optimized KB004 antibody in AML patients by Swords et al.,31
whilst showing a good toxicity proﬁle, did not demonstrate
marked efﬁcacy and fore-shadowed the investigation of ‘armed
antibody’ as a potentially more effective therapy.31 Our previous
studies showed radiolabeled targeting of EphA2 as a potential
therapy target in AML,28 also in glioblastoma models using
β-particle-emitting radioisotope coupled to cIIIA4 antibody resulted
in a targeted antitumor effect in EphA3-expressing tumors.14
In leukemia to avoid bystander cell toxicity, we used an α-particle
emitter, 213Bismuth, which depends on target internalization
because of the high energy and short path length of the α-particle
emission. Here we demonstrated that the IIIA4 antibody could
induce EphA3 internalization, which makes this antibody an ideal
candidate to target payloads including 213Bismuth to the leukemic
cells. Using this form of radioimmunotherapy, we demonstrated
markedly enhanced antitumor effect in mice without signiﬁcant
toxicity. These results strongly suggest that a therapeutic effect of
cIIIA4 on EphA3-positive leukemia can be greatly enhanced by
payloading with an isotope or potentially with cytotoxic drugs, as
has been demonstrated in various hematological malignancies
and solid tumors.31–32
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